Now showing items 1-6 of 6

    • The changing face of prostate cancer diagnosis and management 

      Kumar, Sanjeev Srinivas; Pacey, Simon Christopher
      While early treatment of primary prostate cancer is very effective, the incidence of primary prostate cancer continues to rise and therefore the detection of men with high-risk non-metastatic prostate cancer and their ...
    • Liquid biopsies come of age: towards implementation of circulating tumour DNA 

      Wan, Jonathan; Massie, Charles Edward; Garcia-Corbacho, J; Mouliere, Florent Claude; Brenton, James Derek; Caldas, Carlos Manuel; Pacey, Simon Christopher et al.
      Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a ‘liquid biopsy’ for cancer management. Proof-of-principle ...
    • A Novel Atg5-shRNA Mouse Model Enables Temporal Control of Autophagy in vivo 

      Cassidy, Liam; Young, Andrew; Perez-Mancera, Pedro; Nimmervoll, Birgit; Jaulim, Adil; Chen, Hung-Chang; McIntryre, Dominick et al.
      Autophagy is an evolutionary conserved catabolic pathway whose modulation has been linked to diverse disease states, including age-associated disorders. Conventional and conditional whole body knockout mouse models of key ...
    • Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers 

      Beddowes, Emma Jane; Spicer, J; Chan, PY; Khadeir, R; Corbacho, JG; Repana, D; Steele, JP et al.
      $\textbf{Purpose}$ Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) –negative tumors by converting arginine to citrulline and ammonia. The main aim ...
    • Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer 

      Tan, Chee-Seng; Gilligan, David; Pacey, Simon Christopher (Elsevier, 2015-09-30)
      Discovery of activating mutations in EGFR and their use as predictive biomarkers to tailor patient therapy with EGFR tyrosine kinase inhibitors (TKIs) has revolutionised treatment of patients with advanced EGFR-mutant ...
    • Tumor Necrosis Factor Receptor 2-Signaling in CD133-Expressing Cells in Renal Clear Cell Carcinoma 

      Al-Lamki, Rafia; Wang, Jun; Yang, Jun; Burrows, Natalie; Maxwell, Patrick Henry; Eisen, Timothy George; Warren, Anne Y et al. (Impact Journals, 2016-03-16)
      Compared to normal kidney, renal clear cell carcinomas (ccRCC) contain increased numbers of interstitial, non-hematopoietic CD133+cells that express stem cell markers and exhibit low rates of proliferation. These cells ...